Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2021-10-08 Declaration of Voting R…
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL" (Monthly Information Relating to the Total Number of Voting Rights and Shares Comprising the Share Capital). It explicitly references French regulatory articles (Code de commerce and Règlement Général de l'Autorité des Marchés Financiers - AMF) and provides a table detailing the total number of shares and voting rights as of a specific date (September 30, 2021). This content directly corresponds to notifications regarding changes in the total number of shares and voting rights, which is a specific type of regulatory disclosure. Among the provided codes, 'MRQ' (Major Shareholding Notification) is the closest fit, as these disclosures often accompany or are related to significant ownership changes, although the primary focus here is the total capital structure update. However, looking closely at the definitions, none perfectly match a routine monthly capital structure update based on voting rights. The closest fit that deals with share counts and ownership thresholds is 'MRQ' (Major Shareholding Notification), or potentially 'RNS' (Regulatory Filings) as a general catch-all. Given the specific nature of reporting total voting rights, which is often a prerequisite for major shareholding reports, MRQ is a strong candidate, but since this is a routine monthly update on the *total* capital, and not necessarily a notification *of* a major shareholder crossing a threshold, 'RNS' (Regulatory Filings) is the most appropriate fallback for a specific, non-standard report type, or we must check if any other code fits better. The document is a formal regulatory disclosure about the capital structure. 'MRQ' is for *changes* in significant ownership. Since this is a routine monthly update on the *total* capital, and not a specific report like 10-K, IR, or ER, and it doesn't fit other specific categories (like DIV, DIRS, etc.), 'RNS' (Regulatory Filings) serves as the best general regulatory disclosure category.
2021-10-08 French
Inside Information / Other news releases
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "STATEMENT OF TOTAL VOTING RIGHTS AND SHARES FORMING THE COMPANY'S SHARE CAPITAL" and explicitly references compliance with French Commercial Code and regulations from the Autorité des Marchés Financiers (AMF). It provides a table detailing the number of shares outstanding and the total number of voting rights (gross and net) as of a specific date (September 30, 2021). This type of mandatory periodic disclosure regarding the total number of voting rights is a specific regulatory filing requirement, often related to maintaining transparency about ownership structure and voting power. While it is a regulatory announcement, it specifically deals with voting rights structure, which is distinct from general regulatory filings (RNS) or director dealings (DIRS). However, none of the specific codes perfectly match a 'Total Voting Rights Statement'. The closest related concepts are DVA (Declaration of Voting Results) or potentially RNS (Regulatory Filings) as a fallback. Since this is a statement of the *current* total voting rights structure, not the *results* of a vote (DVA), and it is a specific regulatory disclosure, RNS is the most appropriate general regulatory fallback, although it is highly specific. Given the options, and recognizing this is a mandatory disclosure about the capital structure's voting rights, it is a specific regulatory announcement. If a more specific code existed for 'Total Voting Rights Disclosure', that would be chosen. Lacking that, RNS (Regulatory Filings) serves as the best fit for a mandatory, non-financial, non-management specific regulatory update.
2021-10-08 English
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is explicitly titled "*PRESS RELEASE*" and announces that the company will present data at the 2021 Annual Meeting of the American Society for Radiation Oncology (ASTRO). It details the specific presentations (oral and poster) and provides context about the drug candidate NBTXR3. This format—a formal announcement detailing upcoming corporate or scientific events, often including forward-looking statements and contact information—is characteristic of a general corporate announcement or press release. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a specific regulatory filing like a Director's Dealing (DIRS) or Proxy Statement (PSI), the most appropriate classification is the general regulatory/corporate announcement fallback, RNS (Regulatory Filings), as it serves to inform the market about significant corporate activities (data presentation at a major conference). It is not an announcement *of* a report publication (RPA), but rather an announcement *about* scientific data presentation.
2021-10-06 English
Informations privilégiées / Autres communiqués
Investor Presentation Classification · 95% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces that Nanobiotix will present data at the American Society for Radiation Oncology (ASTRO) 2021 annual meeting. It details the specific presentations (posters and oral presentations) regarding their product NBTXR3, including survival data and combination therapy results. This type of announcement, which details upcoming scientific presentations and data releases, is characteristic of an Investor Presentation (IP) or a general announcement about scientific progress, rather than a formal regulatory filing like a 10-K, an Earnings Release (ER), or a comprehensive Interim Report (IR). Since it is a detailed announcement focused on presenting scientific data to investors and the medical community at a major conference, Investor Presentation (IP) is the most fitting category, as it often includes slides or summaries of the data to be presented, even if the document itself is a press release announcing the event.
2021-10-06 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 100% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces the publication of preclinical data in the 'Red Journal' (International Journal of Radiation Oncology, Biology, Physics). It details scientific findings regarding the product NBTXR3 and its combination therapies. This format—a formal announcement of scientific or business news, often including quotes from management and references to external publications or regulatory filings (like the mention of the 20-F filing in the disclaimer)—is characteristic of a general corporate announcement. Since it is not a full financial report (10-K, IR), a specific financial result release (ER), or a proxy/governance document, the most appropriate classification is the general regulatory announcement/press release category, which aligns best with 'Regulatory Filings' (RNS) as a broad category for non-standard, yet official, corporate communications, or potentially an Investor Presentation (IP) if it were structured as slides, but here it reads like a news release about a publication. Given the content is a press release announcing scientific data publication, RNS (Regulatory Filings/General Announcement) is the best fit among the provided options, as it is not a specific financial report or management disclosure.
2021-09-28 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is explicitly titled "PRESS RELEASE" and announces the publication of preclinical data in the *International Journal of Radiation Oncology, Biology, Physics (Red Journal)*. It details scientific findings, includes quotes from the CEO, provides background on the research, and concludes with standard company information and disclaimers. This format is characteristic of an official announcement intended for the public and investors regarding a specific development, rather than a comprehensive regulatory filing like a 10-K or a quarterly report (IR). Since it is an announcement of scientific/research progress and not a financial result (ER), management change (MANG), or dividend (DIV), it fits best as a general regulatory/corporate announcement. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a press release announcing research findings that doesn't fit a more specific category like ER or MANG, although 'IP' (Investor Presentation) or 'LTR' (Legal/Research Update) could be considered. However, RNS serves as the general regulatory announcement category for non-standard filings. The length (11,319 chars) confirms it is not a short RPA.
2021-09-28 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.